ClinicalTrials.Veeva

Menu
A

Axiom Brain Health | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Remibrutinib
Buntanetap
Remternetug
Trontinemab
MK-2214
MK-2214-004
AL002

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 10 total trials

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). A...

Enrolling
Early Alzheimer's Disease
Biological: MK-2214
Drug: Placebo

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn...

Enrolling
Early Alzheimers Disease
Drug: buntanetap/posiphen
Drug: Placebo

The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from base...

Active, not recruiting
Alzheimer's Disease
Drug: E2814
Drug: Lecanemab

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild c...

Enrolling
Alzheimers Disease
Drug: Trontinemab
Other: Placebo

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

Enrolling
Secondary Progressive Multiple Sclerosis (SPMS)
Drug: Remibrutinib (blinded)
Drug: Placebo

This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosag...

Active, not recruiting
Relapsing Multiple Sclerosis (RMS)
Biological: Ofatumumab approved dose
Biological: Ofatumumab new dose

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Enrolling
Alzheimers Disease
Other: No Intervention

Trial sponsors

Novartis logo
Roche logo
A
A
Eisai logo
G
Lilly logo
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems